Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tadalafil
Drug ID BADD_D02106
Description Tadalafil is a selective phosphodiesterase-5 inhibitor that is used in the treatment of erectile dysfunction (ED), pulmonary arterial hypertension (PAH), and benign prostatic hypertrophy.[L39100, L39105] It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. In contrast to other PDE5 inhibitors like [sildenafil], tadalafil has greater selectivity for PDE5 and a longer half-life which has made it a more suitable option for chronic once-daily dosing in the treatment of PAH.[A242287]
Indications and Usage Used for the treatment of erectile dysfunction.
Marketing Status Prescription
ATC Code G04BE08
DrugBank ID DB00820
KEGG ID D02008
MeSH ID D000068581
PubChem ID 110635
TTD Drug ID D05MQK
NDC Product Code 69238-1348; 16729-370; 42291-787; 68981-043; 62512-0063; 68071-5186; 71205-400; 65862-850; 31722-644; 53747-050; 50268-739; 68071-2613; 71821-008; 72303-0825; 72761-017; 68071-5092; 42291-865; 76420-126; 71610-581; 31722-643; 68071-2553; 69238-1346; 70518-2450; 0002-4463; 27241-113; 60219-1349; 70771-1476; 51293-840; 33342-267; 13668-566; 43598-578; 65862-853; 13668-568; 68071-2451; 63629-8288; 71610-213; 0093-3016; 47335-009; 63629-7943; 0093-3017; 71610-603; 33342-266; 69238-1347; 73377-080; 0110-4464; 66302-467; 0110-4467; 13668-581; 13668-567; 70771-1477; 0093-3019; 67184-0524; 68462-779; 27241-114; 66039-921; 79572-033; 0002-4462; 16729-372; 42291-789; 68180-921; 69238-1349; 75834-249; 68071-4912; 42291-864; 71205-418; 50090-4247; 71335-1255; 47335-011; 62128-0385; 71335-1239; 29300-288; 68180-922; 33342-268; 71821-007; 29300-287; 42291-866; 35573-412; 69037-0015; 69097-374; 65372-1173; 71610-214; 69097-376; 43598-575; 45865-991; 68071-2632; 68462-782; 50090-5724; 47335-012; 0395-8085; 72303-0822; 71052-059; 68382-899; 50268-738; 33342-278; 38779-3062; 65862-851; 50436-0370; 68071-2554; 71335-1670; 62332-178; 69097-375; 43063-236; 16714-077; 60219-1346; 71610-298; 16714-074; 0110-4462; 46144-327; 68071-5116; 68462-781; 27241-123; 65862-852; 63275-9895; 43598-576; 0002-4464; 70518-2862; 69097-526; 68382-898; 62512-0056; 60219-1347; 66174-0021; 71205-268; 31722-645; 46708-177; 27241-112; 62756-028; 31722-646; 71335-1620; 51552-1550; 62332-180; 71610-353; 61919-887; 35573-409; 68071-2421; 50090-4753; 71205-502; 72303-0823; 65862-719; 50090-5344; 71335-1587; 42291-788; 71205-269; 63629-8409; 68462-780; 71610-325; 69097-373; 71610-354; 68180-920; 50090-5627; 47335-010; 60219-1348; 70518-3001; 61919-889; 67835-5045; 68071-5110; 13668-565; 75834-248; 71335-1823; 42291-786; 42291-804; 35573-411; 42291-867; 71610-461; 43353-044; 50090-4660; 67184-0525; 75834-247; 50090-5641; 49452-7596; 71821-009; 68180-919; 29300-286; 35573-410; 71335-1400; 0093-3018; 71610-303; 68071-5272; 46708-841; 70771-1475; 67184-0526; 50379-0005; 68071-5138; 81999-0006; 27241-111; 68180-914; 66039-843; 50090-4276; 51293-842; 46708-178; 43063-969; 68071-5182; 62991-3128; 43353-070; 71610-567; 16729-369; 63415-0117; 67184-0523; 72189-145; 16729-371; 16714-075; 16714-076; 31722-647; 75834-250; 64552-4047; 65862-880; 0110-4463; 43598-573; 68788-8153; 50090-5187; 72789-184; 33342-265; 0002-4465; 70771-1478; 70518-2972; 71335-1884; 43353-857; 90027-004; 46708-179; 62332-179; 63629-8157; 51293-839; 68071-5202; 0093-3334; 46708-180; 43598-574; 71335-1491; 68382-897; 29300-289; 51293-841; 68071-2417; 62332-177; 68382-896; 0110-4465; 63629-4601; 71821-006; 60592-742; 51927-5037; 72303-0824; 71610-324
Synonyms Tadalafil | Pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione, 6-(1,3- benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-, (6R,12aR)- | IC351 | IC-351 | IC 351 | Cialis
Chemical Information
Molecular Formula C22H19N3O4
CAS Registry Number 171596-29-5
SMILES CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Multiple allergies10.01.03.0300.000959%Not Available
Muscle disorder15.05.03.0140.000959%Not Available
Muscle spasms15.05.03.004--
Muscular weakness17.05.03.005; 15.05.06.001--
Musculoskeletal pain15.03.04.0070.003837%
Myalgia15.05.02.0010.013909%
Myocardial infarction02.02.02.007; 24.04.04.009--
Nasal congestion22.04.04.0010.010072%
Nasal dryness22.04.03.0020.000959%Not Available
Nasopharyngitis22.07.03.002; 11.01.13.0020.004796%Not Available
Nausea07.01.07.001--
Neck pain15.03.04.0090.002398%
Neoplasm malignant16.16.01.001--Not Available
Nervous system disorder17.02.10.001--Not Available
Neuralgia17.02.07.0050.002398%
Neuropathy peripheral17.09.03.003--Not Available
Ocular hyperaemia06.04.05.0040.003357%Not Available
Oedema08.01.07.006; 14.05.06.0100.003357%Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.0070.008153%
Oesophagitis07.08.05.001--
Optic ischaemic neuropathy24.04.10.001; 17.04.05.006; 06.07.03.0010.003837%Not Available
Orthostatic hypotension24.06.03.004; 17.05.01.0200.000959%Not Available
Osteoarthritis15.01.04.0010.000959%Not Available
Oxygen saturation decreased13.02.01.0040.004796%Not Available
Pain08.01.08.004--
Pain in extremity15.03.04.010--
Palpitations02.01.02.0030.005276%
Pancreatitis07.18.01.0010.001918%
Pancreatitis acute07.18.01.0020.001918%Not Available
Panic attack19.06.04.0010.000959%Not Available
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 13 Pages